KB407

Gene therapy / editing

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (2)
Cystic Fibrosis
NCT05504837 · Krystal Biotech, Inc.
2023-06-30 – 2027-03 · Cystic Fibrosis
What this study did

Competitive landscape

This drug's own stage for Cystic Fibrosis: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
KB407: this drugPhase 1Gene therapy / editingCFTR (gene replacement)not yet gradedNo reviewed efficacy summary in this indication
Elexacaftor / Tezacaftor / Ivacaftor (Trikafta)ApprovedSmall moleculeCFTR, CFTRReliable signal
NCT03525444: Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results).
NCT03525548: Absolute change in ppFEV1 from baseline at Week 4 vs tezacaftor/ivacaftor: +10.4 vs +0.4; treatment difference 10.0 percentage points (95% CI 7.4 to 12.6), P<0.0001 (TRIKAFTA label section 14.1; CT.gov posted results).
Ivacaftor (Kalydeco)ApprovedSmall moleculeCFTRPartial signal
NCT00909727: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1)
NCT00909532: Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo -0.2 percent of predicted volume (L) (Standard Error 0.7) | 150 mg Ivacaftor q12h 10.4 percent of predicted volume (L) (Standard Error 0.7)
Lumacaftor (Orkambi)ApprovedSmall moleculeCFTRReliable signalNo reviewed efficacy summary in this indication
Tezacaftor / Ivacaftor (Symdeko)ApprovedSmall moleculeCFTRnot yet gradedNo reviewed efficacy summary in this indication
Vanzacaftor / Tezacaftor / Deutivacaftor (Alyftrek)ApprovedSmall moleculeCFTR, CFTRReliable signalNo reviewed efficacy summary in this indication
VX-828Phase 1Small moleculeCFTRnot yet gradedNo reviewed efficacy summary in this indication
LuvomeranDiscontinuedRNA / oligonucleotideCFTR (mRNA replacement)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow KB407 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Cystic FibrosisRecruiting
Est. primary completion 2026-12 · NCT05504837 · CT.gov ↗
What to watch

See the full readout calendar ↗